Patents Assigned to Blanchette Rockefeller Neuroscience Institute
-
Patent number: 8163800Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: GrantFiled: July 28, 2009Date of Patent: April 24, 2012Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Thomas J. Nelson, Daniel L. Alkon
-
Publication number: 20110245307Abstract: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate ?-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.Type: ApplicationFiled: March 8, 2011Publication date: October 6, 2011Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventor: Daniel L. Alkon
-
Publication number: 20110212474Abstract: The present invention provides a method for the diagnosis of AD from non-AD conditions by using a PKC Isozyme Index obtained by determining ratios of ratios of different PKC Isozymes in peripheral cells of a test subject in the absence and presence of a beta-amyloid peptide, and optionally, in the presence of a PKC activator.Type: ApplicationFiled: October 1, 2010Publication date: September 1, 2011Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Tapan Kumar Khan, Daniel L. Alkon
-
Publication number: 20110196028Abstract: This invention provides a method for isolating and identifying proteins participating in protein-protein interactions in a complex mixture. The method uses a chemically reactive supporting matrix to isolate proteins that in turn non-covalently bind other proteins. The supporting matrix is isolated, and the non-covalently bound proteins are subsequently released for analysis. Because the proteins are accessible to chemical manipulation at both the binding and release steps, identification of the non-covalently bound proteins yields information on specific classes of interacting proteins, such as calcium-dependent or substrate-dependent protein interactions. This permits selection of a subpopulation of proteins from a complex mixture on the basis of specified interaction criteria. The method has the advantage of screening the entire proteome simultaneously, unlike two-hybrid systems or phage display methods which can only detect proteins binding to a single bait protein at a time.Type: ApplicationFiled: June 17, 2010Publication date: August 11, 2011Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Patent number: 7977377Abstract: The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.Type: GrantFiled: May 24, 2007Date of Patent: July 12, 2011Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Miao-Kun Sun, Daniel L. Alkon, Thomas J. Nelson
-
Publication number: 20110021508Abstract: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate ?-secretase activity; improve or enhance cognitive ability; and or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.Type: ApplicationFiled: September 16, 2010Publication date: January 27, 2011Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventor: Daniel Alkon
-
Publication number: 20100303792Abstract: The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC.Type: ApplicationFiled: August 5, 2010Publication date: December 2, 2010Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventor: Daniel L. Alkon
-
Patent number: 7803400Abstract: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.Type: GrantFiled: May 24, 2007Date of Patent: September 28, 2010Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Thomas J. Nelson, Daniel L. Alkon, Alessandro Quattrone
-
Patent number: 7682627Abstract: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.Type: GrantFiled: January 3, 2007Date of Patent: March 23, 2010Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Thomas Nelson, Alessandro Quattrone, Daniel Alkon
-
Patent number: 7682807Abstract: A method of diagnosing Alzheimer's disease in a patient comprises determining whether the phosphorylation level of an indicator protein in cells of the patient after stimulus with an activator compound is abnormally elevated as compared to a basal phosphorylation level, the indicator protein being e.g. Erk1/2 and the activator compound being e.g. bradykinin.Type: GrantFiled: February 27, 2002Date of Patent: March 23, 2010Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Wei-Qin Zhao, Daniel L. Alkon
-
Publication number: 20100029744Abstract: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate ?-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.Type: ApplicationFiled: August 10, 2009Publication date: February 4, 2010Applicant: Blanchette Rockefeller Neurosciences InstituteInventor: Daniel Alkon
-
Publication number: 20100022645Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.Type: ApplicationFiled: July 28, 2009Publication date: January 28, 2010Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Thomas J. Nelson, Daniel L. Alkon
-
Publication number: 20100021913Abstract: The present invention relates to a method for diagnosing Alzheimer's Disease (AD) using PKC-elicited gene expression profiles PKC-activation elicits different genomic profiles in AD cells, as compared with control cells, which can he used to diagnose AD and individuals at risk for developing AD.Type: ApplicationFiled: July 28, 2009Publication date: January 28, 2010Applicant: Blanchette Rockefeller Neurosciences InstituteInventors: Daniel L. Alkon, Tapan Kumar Khan
-
Patent number: 7595167Abstract: The present invention is directed to a method of diagnosing Alzheimer's disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's disease, monitoring the progression of Alzheimer's disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's disease. The invention is also directed to kits containing reagents for the detection and diagnosis of Alzheimer's disease using the Alzheimer's disease-specific molecular biomarkers disclosed herein.Type: GrantFiled: October 11, 2005Date of Patent: September 29, 2009Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Tapan Kumar Khan, Daniel L. Alkon
-
Patent number: 7576055Abstract: This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.Type: GrantFiled: May 21, 2007Date of Patent: August 18, 2009Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Thomas Nelson, Alessandro Quattrone, Daniel Alkon
-
Publication number: 20090041667Abstract: The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.Type: ApplicationFiled: May 18, 2005Publication date: February 12, 2009Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Miao-Kun Sun, Daniel L. Alkon
-
Patent number: 6825229Abstract: The present invention relates to compositions and methods to modulate &agr;-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: GrantFiled: June 13, 2002Date of Patent: November 30, 2004Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Patent number: 6821979Abstract: The present invention relates to the combination of a methylxanthine and a carbonic anhydrase activator to provide synergistic effects. The invention further relates to the improved/enhanced cognitive ability of individuals, particularly those suffering from various disorders, such as Alzheimer's Disease, stroke, hypoxia, general dementia, ADHD, mental retardation, and “sun down” syndrome.Type: GrantFiled: June 17, 2002Date of Patent: November 23, 2004Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Daniel L. Alkon, Miao-Kun Sun